Are you Dr. Chen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
145 Michigan St NE
Suite 3100
Grand Rapids, MI 49503Phone+1 616-954-9800Fax+1 616-954-2116
Summary
- Dr. Yuanbin Chen, MD is an oncologist in Grand Rapids, Michigan. He is currently licensed to practice medicine in Michigan, District of Columbia, and Maryland. He is affiliated with Corewell Health - Butterworth Hospital, Trinity Health Grand Rapids Hospital, and Corewell Health Greenville Hospital.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Westchester Medical CenterResidency, Internal Medicine, 2009 - 2012
NYU Grossman School of MedicineInternship, Transitional Year, 2008 - 2009
Sun Yat-Sen University of Medical ScienceClass of 1998
Certifications & Licensure
MI State Medical License 2014 - 2027
DC State Medical License 2014 - 2014
MD State Medical License 2012 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsRESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang
Journal of Clinical Oncology. 2024-07-01 - 12 citationsDurvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta
Clinical Cancer Research. 2024-02-16 - 44 citationsIpilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.Ari VanderWalde, Shay L Bellasea, Kari L Kendra, Nikhil I Khushalani, Katie M Campbell
Nature Medicine. 2023-09-01
Press Mentions
Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023- Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaSeptember 11th, 2022
- Yuanbin Chen, M.D., PhD. – Cancer & Hematology Centers of Western Michigan, PCMay 14th, 2021
- Join now to see all
